338 related articles for article (PubMed ID: 34089122)
1. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
[TBL] [Abstract][Full Text] [Related]
2. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
4. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Muto S; Kawano H; Higashihara E; Narita I; Ubara Y; Matsuzaki T; Ouyang J; Torres VE; Horie S
Clin Exp Nephrol; 2015 Oct; 19(5):867-77. PubMed ID: 25663351
[TBL] [Abstract][Full Text] [Related]
5. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
[TBL] [Abstract][Full Text] [Related]
7. A
Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
Lioudis M; Zhou X; Davenport E; Nunna S; Krasa HB; Oberdhan D; Fernandes AW
BMC Nephrol; 2023 Jun; 24(1):182. PubMed ID: 37349694
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Dandurand A; Ouyang J; Czerwiec FS; Blais JD;
Nephrol Dial Transplant; 2018 Mar; 33(3):477-489. PubMed ID: 28379536
[TBL] [Abstract][Full Text] [Related]
10. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Edwards ME; Chebib FT; Irazabal MV; Ofstie TG; Bungum LA; Metzger AJ; Senum SR; Hogan MC; El-Zoghby ZM; Kline TL; Harris PC; Czerwiec FS; Torres VE
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1153-1161. PubMed ID: 30026287
[TBL] [Abstract][Full Text] [Related]
12. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
[TBL] [Abstract][Full Text] [Related]
14. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O
Clin J Am Soc Nephrol; 2020 Dec; 16(1):48-58. PubMed ID: 33376102
[TBL] [Abstract][Full Text] [Related]
16. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS;
N Engl J Med; 2012 Dec; 367(25):2407-18. PubMed ID: 23121377
[TBL] [Abstract][Full Text] [Related]
18. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
[TBL] [Abstract][Full Text] [Related]
20. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
